CENTENE CORP

CENTENE CORP (CNC) — Investment Memo

🐂 The Bull Case (Warren's voice)

• The Government Toll Booth: This is a play on the inevitable. As the US population ages and poverty persists, the government must spend more on Medicare and Medicaid. Centene is the infrastructure through which those billions flow.
• Scale as a Barrier: While the "moat" is regulatory, the operational moat is the ability to manage millions of high-risk lives. A newcomer cannot simply wake up and manage a statewide Medicaid contract; the administrative complexity is a formidable wall.
• Mean Reversion: If management stops the "empire building" and focuses on the core Medical Loss Ratio (MLR), the sheer volume of premiums provides a massive foundation for recovery.
• The "Cheap" Entry: This becomes attractive only when the market prices it as a dying business, while the government remains obligated to use it. We look for a price that ignores the temporary noise of the 2025 losses and focuses on the perpetuity of government health spending.

🐻 The Bear Case (Charlie inverts)

“Show me where I'll die and I won't go there.”

• The "Middleman Deletion": The existential threat is a shift toward a single-payer system or a government-led overhaul that removes the private administrator. If the government decides to cut out the middleman to save 2%, Centene's "permission slip" becomes a scrap of paper.
• The Margin Squeeze (Price Taker Trap): Centene has zero pricing power. They are price takers in a game where the payer (the government) is perpetually broke and looking to cut reimbursements. A permanent structural decline in margins turns this into a "value trap" where revenue grows but profits vanish.
• The Capital Destruction Spiral: The trend from 9.5% to -33.4% ROE is not a "dip"; it is a collapse. When FCF turns negative (-$0.5B) while NI claims a profit, the business is consuming itself to stay alive.
• Most Likely Death: The Margin Squeeze. The government will continue to tighten reimbursement rates faster than Centene can optimize care. This is a slow bleed that leads to permanent impairment over the next 3–5 years.

💰 Valuation & Margin of Safety

The DCF provided assumes 15% FCF growth—a fantasy given the current trajectory of negative FCF and cratering ROE.

• Intrinsic value estimate: $314.77 (Based on optimistic DCF)
• 25% margin of safety entry: $236.08 (Conservative)
• 50% margin of safety entry: $157.38 (Buffett's ideal)
• Current Status: Dangerously deceptive. While the price may look "cheap" relative to a theoretical DCF, the business is currently an operating disaster. The DCF assumes a healthy company; the 10-K describes a patient in the ICU.

Verdict: PASS

The disconnect between the optimistic DCF and the catastrophic ROE/FCF is a flashing red light. We do not buy "cheap" businesses that are actively destroying capital at a rate of -33.4%. There is no moat when you have the pricing power of a wet noodle.